Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
PR Newswire•04/11/2026•09:01 ET
0
Key Highlights
- ➤SENTRY week 48 selinexor-ruxolitinib myelofibrosis data selected for ASH oral presentation
- ➤SENTRY-2 selinexor monotherapy data selected for ASH oral presentation
- ➤STOMP Arm 12 selinexor-mezigdomide-dexamethasone multiple myeloma data selected for poster
- ➤Chapter 11 plan says Karyopharm common and preferred stockholders receive no distribution
- ➤Karyopharm expects existing equity securities to have no value and complete investor losses
Expert Statements
Reshma Rangwala, Chief Medical Officer and Head of Research of Karyopharm
“New data from SENTRY continues to highlight the promising clinical activity achieved with the combination of selinexor plus ruxolitinib in patients with myelofibrosis, with ongoing benefit observed through week 48.”
Reshma Rangwala, Chief Medical Officer and Head of Research of Karyopharm
“I am also encouraged by early data from the Phase 2 SENTRY-2 trial where selinexor is being evaluated as a monotherapy, with an optional add-on of a JAK inhibitor. Data from the 60 mg cohort of SENTRY-2 support monotherapy selinexor activity in JAKi-naïve myelofibrosis.”
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) PR Newswire
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation –
Get started
Create a free account to read the full story.